Here are four things to know.
- MEDI2070 is an anti-inflammatory drug undergoing clinical trials for the treatment of Crohn’s disease and ulcerative colitis.
- Parsippany-Troy Hills, N.J.-based Allergan purchased the exclusive global rights to MEDI2070 for an upfront payment of $250 million, with the potential for future milestone payments of up to $1.27 billion.
- Gaithersburg, Md.-based MedImmune is developing MEDI2070 through a collaboration agreement with Amgen, headquartered in Thousand Oaks, Calif. London-based AstraZeneca will give Amgen one-third of the royalties it receives from Allergan.
- The deal is expected to close in the fourth quarter of 2016.
More articles on supply chain:
Supply chain tip of the week: Use data to motivate change
Drugmakers bid on Bayer’s dermatology division
3 ways augmented reality devices could improve supply chain
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
